Interpace Biosciences (OTC: IDXG) reported Q1 EPS of $0.10, $0.29 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $12 million.

For earnings history and earnings-related data on Interpace Biosciences (IDXG) click here.